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Introduction
Insulin-like growth factor-I is encoded by IGF-I
gene, composed of 6 exons. Its biological functions
are mediated by the activation of a specific receptor
(IGF-IR). IGF-I exerts a series of significant effects,
including remarkable proliferation and differentia-
tion of target cells [27]. It also participates in the
control of apoptosis, protecting both normal and
tumor cells from this process. Its promoting role has
been demonstrated in a number of human malignan-
cies [25]. Increased serum IGF-I levels have been
shown to be carcinogenesis predictor in some human
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Abstract: Little is known about IGF-I expression in the alveolar lymphocytes (AL), and about local role of IGF-I in phy-
siological conditions and in interstitial lung diseases.  Bronchoalveolar lavage was carried out in patients with silicosis,
asbestosis, idiopathic pulmonary fibrosis (IPF) and sarcoidosis, as well as in control subjects (n=13, 9, 12, 56, 15, resp).
Alveolar macrophages (AM) and lymphocytes (AL) were studied for (1) IGF-I, BCL-2, Fas and Fas Ligand expression and
(2) cell cycle (incl. sub-G1 peak of late apoptosis) with propidium iodide (PI). Flow cytometry (FC) and immunocyto-
chemistry were used. AL early apoptosis was detected by Annexin V FITC/PI staining. IGF-I was present in AL of all test-
ed groups. The number of IGF-I positive AL was significantly higher in IPF (52 ± 6.7%) and in later (II and III) stages of
sarcoidosis (39 ± 7.8 vs 16 ± 4.0% in controls, p<0.05). Increased BCL-2 expression in AL was detected in IPF and sar-
coidosis. In all tested groups, AL were almost exclusively Fas+ T cells. Generally, a low number of AL entered apoptosis;
no significant differences were found between patient groups, except decreased apoptosis rate in sarcoidosis (0.60 ± 0.17 vs
1.15 ± 0.33% in controls, p<0.05). Proportion of AL positive for IGF-I was significantly correlated with parameters reflect-
ing AL and AM cell proliferation and BCL-2 expression (e.g. AL IGF-I+ vs AM in S phase of cell cycle: rs = +0.50,
p=0.001), but not with apoptosis. The results show that human alveolar lymphocytes express IGF-I in normal conditions, as
well as in ILD. The proportion of IGF-I+ lymphocytes was significantly increased in IPF and at later stages of sarcoidosis.
In our material there was no evidence for profibrogenic or antiapoptotic activity of IGF-I. We suggest that IGF-I originat-
ing from AL may be locally active as a mitogen for alveolar macrophages and lymphocytes in ILD.
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organs, such as brain, breast, ovary, prostate, colon
and lung [30].
In the lower airways, IGF-I is permanently present.
Its concentration in homogenized lung tissue of healthy
subjects is about 234 mU/g [5]. Biological role of IGF-
I in lungs includes tissue developmental growth, repair
processes and compensatory growth of healthy lung,
which appears after contralateral pneumonectomy [8,
19]. Alveolar macrophages are usually considered to be
the main local source of IGF-I: the commonly used for-
mer name of insulin-like growth factor-I was alveolar
macrophage derived growth factor, AMDGF [18].
IGF-I is regarded to participate in the pathogenesis
of many interstitial lung diseases (ILD), including sar-
coidosis, idiopathic pulmonary fibrosis (IPF) and pneu-
moconioses (silicosis and asbestosis). It potentially acts
as a mitogen for lung fibroblasts and, subsequently, as
an activator of pulmonary fibrosis [10, 23]. 
In sarcoidosis, increased IGF-I level is considered to
stimulate collagen synthesis by pulmonary fibroblasts
[2]. In IPF, the enhanced local IGF-I expression seems
to affect fibroblast growth and local collagen synthesis
[31]. Increased IGF-I secretion was also observed in
alveolar macrophages originating from silicosis and
asbestosis patients [9, 21]. High surface expression of
IGF-I receptor on AM could explain intensive
macrophage proliferation observed in this subgroup of
ILD [26]. It should be emphasized that all the mentioned
disorders might be complicated by disseminated pul-
monary fibrosis, resulting in severe respiratory failure
and fatal outcome [24]. However, both in ILD patients
and in normal conditions, little is known about IGF-I
expression in cells other than alveolar macrophages.
Apoptosis seems to be a powerful mechanism par-
ticipating in the pathology of lower airways in ILD [1].
The imbalance of prosurvival and proapoptotic signal-
ing pathways in such cells as alveolar macrophages
(AM) and lymphocytes (AL) may play an important
role in the onset, progress and remission of ILD [22].
For example, the reduced apoptosis of alveolar lympho-
cytes was demonstrated in inflammatory diseases, char-
acterized by high BAL lymphocytosis, such as extrinsic
alveolitis and sarcoidosis [17, 28]. Recently, we report-
ed similar findings in lung pneumoconioses [29]. 
In order to explain the dysregulation of pro-
grammed cell death observed in ILD, many investiga-
tors focused their attention on different components of
antiapoptotic pathways, e.g. on interleukine-2 (AL in
sarcoidosis), transforming growth factor-β (immune
cells in pulmonary fibrosis), intracellular BCL-2 or
BCL-XL expression (AL in sarcoidosis and extrinsic
alveolitis), transcription factor NF-κB (AM in pneu-
moconioses) or surfactant protein D (experiments on
murine AM) [4, 6, 17]. It should be emphasized, how-
ever, that the mechanisms responsible for normal
immune cell apoptosis (the event that seems to be not
very common in physiological conditions), as well as
for its extremely reduced rate in some lower airway dis-
orders, are poorly understood. The role of IGF-I, which
is probably active locally as a mitogen, profibrotic
cytokine and antiapoptotic agent together, needs also
more accurate explanation. 
The purpose of the present study was to determine
the expression of IGF-I in the alveolar immune cells
both lymphocytes and macrophages in ILD, such as sar-
coidosis, idiopathic pulmonary fibrosis, asbestosis and
silicosis. The results of IGF-I expression, calculated
separately for AL and AM, were referred to the clinical
data and to the parameters characterizing the apoptosis
and proliferation of immune cell. Especially, in the
material coming from relatively large group of patients,
we tested the statistical correlations between the per-
centage of IGF-1-positive alveolar macrophages and
lymphocytes and (1) the predicted value of vital capac-
ity (VC), which decline in ILD serves as a clinical mark-
er of lung fibrosis; (2) the percentage of apoptotic AM
and AL (3) the rate of AM and AL proliferation (S and
G2M phases of the cells cycle). In this way we tried to
assess the profibrotic, antiapoptotic and mitogenic role
of IGF-I in interstitial lung diseases. 
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Table 1. Anti-human monoclonal antibodies used for immunocy-
tochemical staining (ICS) and flow cytometry (FC)
Materials and methods
Patients. The cytological material originating from bronchoalveo-
lar lavage (BAL) was harvested from 90 patients with ILD, i.e. sar-
coidosis (56 cases), asbestosis (9), silicosis (13) and idiopathic pul-
monary fibrosis (12). A diagnosis of sarcoidosis was established in
accordance with recently described criteria [12]. In all patients
non-caseating granulomas were identified by transbronchial or
endotransbronchial biopsy. None of patients included in the study
had previously been treated with steroids. Patients were subdivid-
ed according to conventional chest X-ray staging. 
A diagnosis of pneumoconiosis (asbestosis or silicosis) was
established according to chest X-ray standards of International
Labor Organisation in subjects with proven professional or envi-
ronmental (as happened in some cases of asbestosis) exposition to
the respective inorganic dust. In these patients the exposition was
additionally determined by BAL cytology, including the presence
of ferrugineous bodies in asbestosis and silica dust light emission
in polarized light in silicosis [15, 29].
Fifteen persons diagnosed for ILD, in which complete clinical
investigation (incl. lung function tests, chest X-rays, DLCO and
arterial blood gas analyses) finally excluded any lung pathology,
served as the control group. They did not present any signs of
infection or chronic lung disease and they were not treated with
corticosteroids, immunosuppresive agents or any other drugs
known as a potential ILD cause. 
All involved subjects were nonsmokers. In this way we omit-
ted the data interpretation problems concerned with distinct
cytoimmunological pattern observed in the group of smokers [11].
Bronchoalveolar lavage (BAL). BAL was carried out according
to criteria of European Respiratory Society [13]. In brief, the
patients were premedicated with midazolam 2.5-5.0 mg i.v., fol-
lowed by local anesthesia of upper airways with 2% lidocaine solu-
tion. The Olympus Bf 20 bronchofiberoscope was inserted into the
middle lobe or into the left lung lingula, alternatively. Lavage with
200 ml of 0.9% NaCl sterile solution (37°C) was carried out by
sequential instillation of four 50 ml aliquots of saline. The BAL
fluid fractions were retrieved carefully by gentle suction, then
pooled and filtered. The fluid recovery was calculated as the per-
centage of the instilled volume. The material was immediately sent
to the laboratory. 
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Fig. 1. Examples of BAL immunocytochemistry are presented in the micrographs. A. In contrast to alveolar macrophages, alveolar lym-
phocytes (AL) demonstrate moderate expression of IGF-I. Only some AL are intensely positive. Flow cytometry is more sensitive (see
Fig. 2). Sarcoidosis, counterstained with Harris hematoxylin, × 200. B. BAL cytospin preparation with relatively high percentage of pos-
itive lymphocytes. Asbestosis, counterstained with Harris hematoxylin, × 200. C. One of four AL is positive. It should be emphasized that
positive alveolar lymphocytes frequently adhere to macrophages. Some AM present both cytoplasmic and superficial IGF-I expression
(they absorb cytokine from microenvironment by IGF receptors?). Control group, counterstained with Harris hematoxylin, × 600. 
D. Common superficial expression of Fas (CD95) on BAL immune cells. Control group, counterstained with Harris hematoxylin, × 200.
BAL routine cytology. The total cell count and cell viability (try-
pan blue exclusion test) were calculated, as described before. BAL
cytospin smears were stained simultaneously with hematoxylin-
eosin (HE) and May-Grünwald-Giemsa (MGG). In each sample
the differential count of BAL reactive cells was calculated as the
mean result of both methods (at least 500 cells were counted) [14]. 
BAL immunocytochemistry. The immunocytochemical proce-
dure was performed on samples obtained by BAL material cyto-
centrifugation (100-300 µl of native BAL fluid, Shandon, Cytospin
3, 1000 rpm, 5 min followed by fixation in 70% ethanol, 10 min,
stored at -80°C). The avidin-biotin-peroxidase method was used
(LSAB 2 System, DAKO Cytomation, cat. no K0675). The
immunostaining procedure was carried out using mouse anti-
human monoclonal antibodies (MoAbs) directed against CD95,
IGF-I and BCL-2 (details listed in Table 1), diluted in Antibody
Diluent (Dako Cytomation, no S2022). As negative controls, we
replaced primary antibodies with nonspecific mouse IgG1.
After rehydration, endogenous peroxidase activity was blocked
by incubation with 3% hydrogen peroxide in PBS (5 min).
Cytospin smears were then washed in TBS, blocked with 3%
bovine serum albumin (BSA, POCh, 30 min, room temperature) to
inhibit nonspecific immunoreactivity and incubated overnight at
4°C with the monoclonal antibodies (data in Table 1). Alternative-
ly, the wet chamber incubation with diluted MoAbs at room tem-
perature, 1 h, was carried out. Consecutive incubations were con-
ducted with biotinylated anti-mouse secondary antibody (50 µl)
and horseradish peroxidase solution linked with streptavidin
(Streptavidin-HRP, 50 µl, LSAB 2 Systems, DAKO Cytomation,
no K0675). Both incubations were carried out at room temperature
for 15 min, and slides were rinsed 3× in TBS before each incuba-
tion. Diaminobenzidine (DAB) was used as chromogen. The slides
were rinsed with TBS buffer, pH 7.6 (Trismabase SIGMA, cat. no
K5458) in NaCl solution, counterstained with Harris hematoxylin
(2-5 min), rinsed in water, dehydrated with use of graded alcohols
(50% 70% 90% and 99%, 5 min each), bathed in fresh xylene and
covered with glycerol jelly. The cells were evaluated in light
microscope. In each slide we counted at least 250 cells (500 on the
average), calculating separately the percentage of positive
macrophages and positive lymphocytes [14]. Intracellular expres-
sion of IGF-I and surface staining for Fas (CD95) are presented in
Figure 1. 
BAL immune cell phenotyping. BAL material was centrifuged
(300× g, 10 min) and a cell pellet was resuspended in PBS to 2-10
× 106 cells per ml. The samples containing 50 µl of cell suspension
were incubated with mixture of saturating amounts of MoAbs for
30 min in the dark. Double- or three-colour typing was performed,
according to the percentage of AL (more or less than 5% of BAL
reactive cells, respectively). Mouse anti-human MoAbs directed
against superficial CD3, CD 4, CD8, CD16+56, CD19, CD45,
CD95 and CD178 antigens, fluorochrome-conjugated (FITC or
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Fig. 2. FC analysis of IGF-I expression in AL and AM. Alveolar lymphocyte and macrophage gates are defined in flow cytometry due to
cell CD45 expression and side scatter, SSC (upper left panel, gate R1 and R2 respect.) and then redefined, i.e. back-gated, acc. to
FSC/SSC parameters (upper right panel, gate R3 and R4 respect.). Sample of AL (R3) gate analysis for IGF-I expression in left lower
panel; parallel analysis of AM (R4) gate in right lower panel. About 30% of AL and > 95% of AM are positive. Markers set according to
the negative isotype control. SSC presented in logarithmic scale in order to visualize dot plot of macrophages. 
PE) were used in the study (Becton Dickinson Immunocytometry
Systems, BDIS, Mountain View, CA, USA; R & D Systems, data
in Table 1). Negative isotype control was used in sample series of
every patient. After incubation, cells were washed in PBS (300× g,
10 min) and resuspended in 300 µl of PBS containing 1%
formaldehyde [3, 14]. 
Flow cytometry was also applied to test BAL cell IGF-I and
BCL-2 expression. The samples containing 50 µl of BAL cell sus-
pension were preincubated with 0.3% saponin (200 µl, 10 min),
washed in 0.1% saponin (1 ml, 300× g, 5 min) and incubated with
saturating amounts of the respective MoAb (in 100 µl of 0.3%
saponin, 30 min in the dark). Cells were washed and incubated
with the secondary antibody (rabbit anti-mouse FITC conjugated
serum, DAKO Cytomation, cat. no F031302) for 10 min in the
dark. The same secondary antibody was used as negative control
(primary MoAb was omitted). The cells were washed twice with
PBS and resuspended in 300 µl of PBS with 2% formaldehyde for
immediate flow cytometric analyses.
Early apoptosis detection with Annexin V FITC/PI staining.
Detection of early apoptosis in BAL lymphocytes was performed
according to the instruction of manufacturer (APOPTEST™-
FITC, DAKO Cytomation, cat. no K2350). In brief, fresh BAL
cells (105-106 cells/ml) were washed, resuspended in 96 µl of ice-
cold diluted binding buffer and incubated with 1 µl Annexin V-
FITC and 2.5 µl propidium iodide for 10 min in the dark. The cell
sample was diluted with 250 µl of binding buffer and then meas-
ured immediately by flow cytometry. Negative control was carried
out for each sample (incubation with binding buffer alone). For
positive control, the cells were incubated on ice with 3% formalde-
hyde in binding buffer for 30 min [29]. 
Late apoptosis detection with cell permeabilization and PI
staining. BAL cells (1-2 × 106) were washed in PBS, resuspended
in 0.03% Nonidet solution with 0.005% propidium iodide (PI),
centrifuged (400 × g, 5 min) and incubated with 250 µl of the
Nonidet/PI solution (room temperature, 15 min in the dark). The
next incubation was carried out for 15 min with 250 µl of RNAse
solution (88 Kunitz U per 100 ml PBS, room temperature, in the
dark). The cells were finally suspended in 1 ml volume (adjusted
with PBS) and acquired in FACSCalibur flow cytometer (BDIS)
within 24 h from staining [29]. 
Flow cytometry. All BAL materials included in the study fulfilled
the precise criteria of cytometric analyses, which were commented
on elsewhere [14]. FC data were acquired within 24 h after stain-
ing, using CellFit software and FACSCalibur cytometer (BDIS).
An argon ion laser excitation 488 nm was used. The emitted light
was detected by logarithmic amplification through barrier filters
specific for the emission range of the different fluorophores:
530/22 nm for FITC (fluorescence channel FL1), 585/42 nm (FL2)
for PE and >650 nm (FL3) for PE Cy5. In each sample 8000-12000
events (cells) were acquired. 
Gates for AL and AM were determined due to the cell granu-
larity (side scatter, SSC) and intensity of staining with CD45 FITC
("back gating"). The sample was presented in Figure 2. The results
of lymphocyte typing and lymphocyte early apoptosis detection
were yielded by quadrant analyses of FL1 vs FL2 channel dot plot
and were presented as the percentage of gated lymphocytes [29]. 
For detection of late apoptosis, cells were acquired with the use
of pulse processor. Cell cycle was assessed simultaneously. The
conjunction of two gates was applied: forward scatter (characteriz-
ing cell size) vs side scatter (FSC vs SSC), as well as pulse width
vs pulse area in a fluorescence-2 standard channel (FL-2W vs FL-
2A). Data on 15 000-20 000 BAL cells were collected and ana-
lyzed with BDIS ModFit software. The sample was presented in
Figure 3. Two distinct FSC/SSC gates were applied for separate
AL and AM apoptosis/cell cycle FC analyses. 
Statistical analysis. All BAL cytology and phenotype results were
presented as medians ± SEM (due to nonparametric distribution of
values) [20]. The Mann-Whitney U-test was used to compare the
data obtained in analyzed groups (ILD patients vs controls). The
Spearman's rank correlation coefficient rs was applied to test the
correlation between two random variables. P-values < 0.05 were
considered statistically significant. 
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Fig. 3. Late apoptosis and cell cycle
analysis of AL gate - samples of silico-
sis (the upper panel) and asbestosis (the
lower panel). Generally, AL late apop-
tosis (marker 1, M1) in the majority of
examined ILD patients is uncommon as
determined with the use of PI; the rela-
tively frequent AL apoptotic rate (>6%
in presented asbestosis sample) occurs
rarely. Another characteristic feature of
BAL material is a relatively low per-
centage of proliferating AL (G2/S/M
phase, marker 2, M2). 
Results
The basic information about groups included in the
study, as well as their BAL cytological and immuno-
logical data, are presented in Table 2. Increase in BAL
total cell number was found in all tested groups, as
compared with controls. Silicosis was characterized by
higher percentage of alveolar macrophages and a rela-
tive decline in BAL lymphocytes. In asbestosis,
increased percentage of AM and neutrophils together
with high CD4/CD8 ratio was found. IPF was charac-
terized by increase in proportion of BAL lymphocytes,
neutrophils and eosinophils; CD4/CD ratio was low.
BAL distinct lymphocytosis together with mild
eosinophilia and typical high CD4/CD8 ratio was
characteristic for sarcoidosis patients.
AL population, in contrast to the respective periph-
eral blood results, was dominated by T cells with only
few NK and B cells, regardless of the tested group
(data not shown). Additionally, in all groups, up to
100% of AM, Th (CD4) and Tc (CD8) cells expressed
CD95 marker, suggesting high AM and AL suscepti-
bility to proapoptotic stimuli. The results of Fas
Ligand (CD178) expression on AL are presented in
Figure 4. The percentage of CD178-positive AL was
increased in asbestosis, and in IPF (for Tc cells only);
it was decreased in total sarcoidosis, as compared with
controls. However, we did not observe any association
between Fas Ligand expression on AL and the number
of apoptotic BAL immune cells. 
Almost all AM, according to immunocytochemical
staining, were positive for IGF-I: from 88 ± 4.9 (77-
100)% in IPF to 93 ± 5.5 (44-100)% in sarcoidosis and
95 ± 3.8 (75-100)% in silicosis. The respective values
for asbestosis and controls were 91 ± 3.7 (81-99)% and
94 ± 1.3 (91-97)%. There were no significant differ-
ences in IGF-I and BCL-2 expression in AM between
the tested groups. 
Results of intracellular expression of IGF-I and
BCL-2 in alveolar lymphocytes (data from flow
cytometry) were presented in Figure 5. Sarcoidosis
was subdivided according to the disease stages. 
A noticeable number of alveolar lymphocytes
expressed IGF-I. The percentage of IGF-I-positive
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Table 2. Patients' data and BAL cytoimmunology in interstitial lung diseases (ILD)
M - male, F - female; # Data presented as mean ± SD (range); other results presented as median ± SEM (range);
*P < 0.05 as compared to controls; **P < 0.01 as compared to controls
lymphocytes was significantly higher in IPF (52 ± 6.7,
range: 5-67%) and in later radiological sarcoidosis
stages (39 ± 7.8, range: 6-88%) than in controls (16 ±
4.0, range: 6-18%, p<0.05). Changes observed for
stage I of sarcoidosis (25 ± 6.7, range: 2-65%), silico-
sis (17 ± 7.8, range 5-38%) and asbestosis (34 ± 7.2,
range 3-50%) were statistically insignificant. IGF-I
expression was found in both major T cell subsets (Th
and Tc, data not shown).
Significantly increased percentage of AL express-
ing BCL-2 was detected in IPF and sarcoidosis.
The results of cell cycle and apoptosis examination
are summarized in Table 3. Decreased apoptosis rate -
both early and late one - was characteristic for AL in
sarcoidosis, regardless of the stage of the disease
(p<0.05). IPF was characterized by significantly high-
er rate of proliferating AL (cells of G2/S/M phase). 
The percentage of IGF-I-positive alveolar lympho-
cytes was strongly and positively correlated with
parameters reflecting proliferation of both AL and AM
(Fig. 6). However, the percentage of alveolar
macrophages expressing IGF-I was correlated only
with the respective data concerning AM alone and it
was not related to any parameters of alveolar lympho-
cyte proliferation. Surprisingly, despite the positive
correlation between the percentage of IGF-I-positive
AL and the proportion of BAL cells carrying BCL-2,
no relation between immune cell IGF-I expression and
any parameters characterizing their apoptosis was
found. 
The percentage of AL and AM expressing IGF-I
was not correlated with any values of lung function
tests, including VC and FEV1/VC.
Discussion
It has been known for many years that almost all AM
secrete IGF-I as so called alveolar macrophage-
derived growth factor, AMDGF. In the present study
we have proven that the expression of IGF-I is also
present in alveolar lymphocytes. In opposite to alveo-
lar macrophages, which are almost all IGF-I+ in every
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Fig. 4. Expression of Fas Ligand
(CD178) - alveolar lymphocytes in
ILD. Flow cytometry. Data presented
as medians ± SEM of AL positive for
CD178; *p < 0.05; **p <0.01 as com-
pared to controls. 
Fig. 5. Expression of IGF-I and BCL-2
- alveolar lymphocytes in ILD. Flow
cytometry. Data presented as medians
± SEM of AL positive for BCL-2; 
*p < 0.05 as compared to controls; 
**p < 0.01 as compared to controls.
tested individual, our results obtained in alveolar lym-
phocytes were different in some groups of patients, i.e.
percentage of IGF-I-positive AL was significantly
higher in IPF and in the later stages of sarcoidosis as
compared to the control group. 
It should be established what is an actual impor-
tance of IGF-I, including AL-derived IGF-I in the
lower airways. 
First of all, it has been considered for many years
that IGF-I is active as a local fibroblast stimulator and
profibrotic factor [8]. The secretion of IGF-I as well as
expression of IGF-receptor were increased in BAL
macrophages of patients with pneumoconioses and in
AM of experimental animals exposed to silica [9, 26].
However, it should be emphasized that in large group
of patients analyzed in the current study we did not
observe any negative correlation between IGF-I
expression and predicted value of VC. These results
were in general consistent with some recent studies. In
one of them, Krein et al. [16] suggested that IGF-I in
lower airways, contrary to TGF-β, protects epithelial
cell layer from injury and apoptosis. They questioned
the link between IGF-I and interstitial fibrosis in ILD.
The profibrotic role of IGF-I has not been confirmed in
two other studies by Mustaers et al. [21] and Vanhee et
al. [32], who examined statistical correlations in BAL
fluid of asbestosis and coal workers' pneumoconiosis
patients. Furthermore, in BAL of IPF patients analyzed
by Pala et al. [23], IGF-I level was positively correlated
with the results of lung function tests. We conclude that
IGF-I does not stimulate lung fibrosis in clinical condi-
tions, despite findings from experimental studies. 
Secondly, since IGF-I protects many cell types
from apoptosis [27], we have tried to relate the results
of IGF-I expression in BAL immune cells to data char-
acterizing apoptosis of AL and AM. High proportion
(up to 100%) of both T lymphocytes and alveolar
macrophages expressed superficial Fas molecules.
Additionally, many of these cells co-expressed Fas lig-
and. Alveolar cells are susceptible then to apoptosis
induced by membrane stimuli. Surprisingly, we found
a relatively low apoptotic rate in both AM and AL,
especially in BAL lymphocytes originating from sar-
coidosis patients. In general, our results obtained in
patients with sarcoidosis were consistent with the
hypothesis on apoptosis resistance of alveolar lympho-
cytes in this disorder [28]. However, account should be
taken of the relatively low AL apoptosis rate obtained
in the current study in other interstitial lung diseases,
as IPF and asbestosis. 
To our surprise, in our material there was no correla-
tion between IGF-I expression in immune cells and the
rate of AL and AM apoptosis. The only finding suggest-
ing the influence of IGF-I on regulation of apoptosis in
the lower airways was a significant positive correlation
between the percentage of alveolar lymphocytes carry-
ing IGF-I and expression of BCL-2 in both AL and AM.
Finally, we have not proven the antiapoptotic activity of
IGF-I in ILD immune cells. This lack of relation could
be explained by the complex character of local interac-
tions between prosurvival and proapoptotic factors [4,
6]. The mechanisms of this interaction have not been yet
fully understood. For example, decreased BCL-2
expression can occur together with very low AL apop-
totic rate in some lung disorders [17].
Thirdly, we expected that IGF-I expression in lower
airways might affect cell proliferation in lower airways
of ILD patients. Actually, the percentage of AL carry-
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Table 3. Cell cycle and apoptosis in interstitial lung diseases (ILD)
All data concern alveolar lymphocytes, except the last two rows concerning alveolar macrophages (AM)
Results are presented as median ± SEM (range), *P < 0.05 as compared to controls
ing IGF-I was positively correlated with proliferation
rate of BAL immune cells. This relation was statisti-
cally significant for both S and G2M phase of cell
cycle in AL as well as AM. However, it should be
emphasized that the immune cell proliferation rate
observed in lung alveoli was in general low, if we take
into consideration the active, extensive inflammation
commonly present in sarcoidosis and other ILD. This
infrequent proliferation may be explained by local
activity of surfactant proteins and other potent mitosis
inhibitors that appear in alveoli [7]. IGF-I seems to be
unable to overcome them. 
The cytological and immunological results
obtained in the present study are in line with data
reported by other authors and with our previous find-
ings, described elsewhere [14, 15, 29]. 
Summing up, human lymphocytes in the lower air-
ways express IGF-I both in normal conditions and in
ILD. The proportion of IGF-I+ lymphocytes is signifi-
cantly increased in IPF and in later (II and III) stages
of sarcoidosis. The local role of IGF-I in normal con-
ditions, as well as in ILD, needs further investigation.
IGF-I seems to be a potent mitogen of alveolar lym-
phocytes and macrophages, but in our material no evi-
dence for its antiapoptotic or profibrotic function in
ILD has been found.
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